Targeting Class B GPCRs to Advance the Next-Generation of Metabolic Therapeutics
Time: 8:30 am
day: Conference Day Two
Details:
- Leveraging a novel drug modality and proprietary discovery platform to unlock Class B GPCRs
- Advancing a pipeline of differentiated therapeutics for obesity and metabolic disorders
- Capturing the untapped potential of Class B GPCRs with novel monotherapy and combination approaches
